Work

A phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab (MSB0010718C) in patients with metastatic Merkel cell carcinoma.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.tps9086

Authors: Howard Kaufman, Omid Hamid, Sandra P. D'Angelo, Guojun Yuan, Kevin M. Chin, Shailender Bhatia, Jean-Marie Cuillerot, Paul Nghiem

Institutions: Rutgers Cancer Institute, Angeles Clinic and Research Institute, Memorial Sloan Kettering Cancer Center, Merck KGaA, Darmstadt (Germany), EMD Serono, Inc. (United States), Merck Healthcare KGaA, Darmstadt (Germany), University of Washington, Fred Hutch Cancer Center, University of Washington Medical Center

Language: English

Topic: Polyomavirus and related diseases

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2601029995

Cites:

Cited by: 2

Related to: 10